Series B - Oculis
Investment Firm
Overview
Oculis is a clinical-stage biopharmaceutical development company focusing on ophthalmic drugs and novel drug delivery.
Announced Date
Jan 04, 2018
Funding Type
Series B
Highlights
Location
Europe
Social
Investor Lead
Bay City Capital
Bay City Capital is a debt and early_stage_venture and late_stage_venture and private_equity firm.
Novartis Venture Fund
Novartis Venture Fund is a early_stage_venture and late_stage_venture and post_ipo and seed firm.
Pivotal bioVenture Partners
Pivotal bioVenture Partners is a convertible_note and early_stage_venture and late_stage_venture and post_ipo firm.
Participant Investors
4
Round Details and Background
Oculis raised $20523598 on 2018-01-04 in Series B
Oculis is a clinical-stage biopharmaceutical development company focusing on ophthalmic drugs and novel drug delivery.
Company Funding History
13
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Mar 01, 2012 |  Grant - Oculis | 1 | - | 63.6K |
| Mar 01, 2011 | Grant - Oculis | 1 | - | 224.6K |
| Mar 01, 2015 | Grant - Oculis | 1 | - | 112.6K |
| Aug 16, 2016 | Series A - Oculis | 2 | - | undefined |
Recent Activity
There is no recent news or activity for this profile.